Lupin Secures FDA Nod for Generic Pepcid Injection
Event summary
- Lupin received FDA approval for its generic version of Pepcid Injection (famotidine) on May 13, 2026.
- The product is bioequivalent to Merck's Pepcid Injection and will be manufactured at Lupin's Nagpur facility.
- Estimated annual U.S. sales for the reference drug were $8.7 million (IQVIA MAT March 2026).
- Indications include treatment of pathological hypersecretory conditions and gastrointestinal disorders.
The big picture
This approval strengthens Lupin's position in the U.S. generics market, particularly in the hospital segment. The move comes as pharmaceutical companies increasingly focus on complex generics to differentiate themselves. With 15 manufacturing sites globally, Lupin is positioning itself as a major player in both branded and generic formulations across multiple therapy areas.
What we're watching
- Market Penetration
- How quickly Lupin can capture market share from Merck's Pepcid Injection in the hospital setting.
- Manufacturing Efficiency
- Whether Lupin's Nagpur facility can scale production to meet U.S. demand without quality issues.
- Regulatory Compliance
- The pace at which Lupin can secure additional FDA approvals for complex generics.
Related topics